Vandetanib | ZD6474;CH 331;Zactima | 凡德他尼(ZD6474) | VEGFR

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	97%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	c-Kit,PDGFR,FGFR	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/Flk1, IC50: 270 nM VEGFR2/KDR, IC50: 37 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms/CSF1R	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/Flk1, IC50: 0.18 nM VEGFR2/KDR, IC50: 0.2 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	c-Kit,BTK	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ hVEGFR2, IC50: 9 nM mVEGF2, IC50: 165 nM	+ hVEGFR3, IC50: 420 nM		99%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			99%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	99%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Apatinib mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	99%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	99%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Cell Line A2780 cells CALU-3 cells HEK293T cells 8505C Hth83 K562 cells H9 cells MEG-01 cells MCF-7 BT-474 HCC827 cells A549 cells H1975 cells	Concentration	Treated Time	Description	References
A2780 cells	500, 750, 1000, 2000, 5000 nM	72 h	To test the inhibitory effect of Vandetanib on A2780 cells expressing RET mutants, the results showed that Vandetanib significantly reduced cell viability in a dose-dependent manner.	J Exp Clin Cancer Res. 2020 Mar 23;39(1):53.
CALU-3 cells	1 μM	12 months	To study the acquired resistance mechanisms of CALU-3 cells to Vandetanib, results showed that CALU-3 cells developed acquired resistance after long-term exposure to Vandetanib, accompanied by epithelial-mesenchymal transition (EMT) features.	Br J Cancer. 2011 Jul 26;105(3):382-92.
HEK293T cells	10 μM	44 h	Vandetanib remarkably reduced SARS-CoV-2 propagation and restored SARS-CoV-2-induced aberrant OXPHOS process and ATP generation.	Signal Transduct Target Ther. 2024 May 11;9(1):125.
8505C	0.59-150 μM	72 h	Vandetanib significantly inhibited the proliferation of 8505C cells, with a GI50 value of 7.56 μM.	Clin Cancer Res. 2011 Apr 15;17(8):2281-91.
Hth83	0.59-150 μM	72 h	Vandetanib significantly inhibited the proliferation of Hth83 cells, with a GI50 value of 3.30 μM.	Clin Cancer Res. 2011 Apr 15;17(8):2281-91.
K562 cells	0.78, 1.56, 3.12 μM	48 h	Vandetanib downregulated EPHB4 protein via the ubiquitin-proteasome pathway and inhibited PI3K/AKT and MAPK/ERK signaling pathways in K562 cells.	Mol Oncol. 2022 Jul;16(14):2747-2765.
H9 cells	0.78, 1.56, 3.12 μM	48 h	Vandetanib significantly inhibited the growth of H9 cells, and its effect was correlated with the expression level of EPHB4.	Mol Oncol. 2022 Jul;16(14):2747-2765.
MEG-01 cells	0.30, 0.60, 1.20 μM	48 h	Vandetanib significantly inhibited the growth of MEG-01 cells and induced apoptosis.	Mol Oncol. 2022 Jul;16(14):2747-2765.
MCF-7	10 μM	48 h	To evaluate the effect of Vandetanib on RET signaling pathway in hormone-sensitive MCF-7 cells and its impact on cell viability. Results showed that Vandetanib significantly reduced phosphorylated RET levels and cell viability without altering total RET expression. Additionally, Vandetanib enhanced the inhibitory effect of Tamoxifen.	Clin Cancer Res. 2014 Apr 15;20(8):2115-25.
BT-474	10 μM	48 h	To evaluate the effect of Vandetanib on RET signaling pathway in hormone-resistant BT-474 cells and its impact on cell viability. Results showed that Vandetanib significantly reduced phosphorylated RET levels and cell viability without altering total RET expression. Additionally, Vandetanib enhanced the inhibitory effect of Tamoxifen.	Clin Cancer Res. 2014 Apr 15;20(8):2115-25.
HCC827 cells	1 μM		Vandetanib almost completely diminished EGFR phosphorylation in HCC827 cells.	Clin Cancer Res. 2009 May 15;15(10):3484-94.
A549 cells	1 μM		Vandetanib caused only a partial reduction in EGFR activation in A549 cells.	Clin Cancer Res. 2009 May 15;15(10):3484-94.
H1975 cells	1 μM		Neither erlotinib nor vandetanib treatment resulted in significant decreases in EGFR phosphorylation in H1975 cells.	Clin Cancer Res. 2009 May 15;15(10):3484-94.

Species Nude mice HACE2 transgenic mice Nude mice BALB/c-nu mice Mice Nude mice Mice	Animal Model CALU-3 cell xenograft model SARS-CoV-2 infection model ATC xenograft model K562 xenograft model MCF-7 xenograft model NSCLC xenograft models MYCN/AlkF1178L neuroblastoma model	Administration	Dosage	Frequency	Description	References
Nude mice	CALU-3 cell xenograft model	Oral	15 mg/kg	Twice daily, 5 days per week, for 5 weeks	To evaluate the antitumour efficacy of the MEK inhibitor MSC19363669B in the CALU-3 cell xenograft model, results showed that MSC19363669B significantly inhibited tumour growth.	Br J Cancer. 2011 Jul 26;105(3):382-92.
HACE2 transgenic mice	SARS-CoV-2 infection model	Oral	25 mg/kg	Once daily for 6 days	Vandetanib significantly reduced SARS-CoV-2 propagation in lung tissue and mitigated SARS-CoV-2-induced lung inflammation.	Signal Transduct Target Ther. 2024 May 11;9(1):125.
Nude mice	ATC xenograft model	Oral gavage	50 mg/kg, 25 mg/kg	Daily for 3-4 weeks	Vandetanib significantly inhibited the growth of ATC xenograft tumors, with tumor volume reductions of 69.32% and 66.56% for Hth83 and 8505C, respectively.	Clin Cancer Res. 2011 Apr 15;17(8):2281-91.
BALB/c-nu mice	K562 xenograft model	Oral	40 mg/kg	Once daily for 14 days	Vandetanib significantly inhibited tumor growth in the K562 xenograft model and induced tumor cell apoptosis.	Mol Oncol. 2022 Jul;16(14):2747-2765.
Mice	MCF-7 xenograft model	Oral	25 mg/kg	Daily for 3 weeks	To evaluate the effect of Vandetanib on tumor growth and metastasis in the MCF-7 xenograft model. Results showed that Vandetanib significantly inhibited tumor growth and reduced tumor cells in the lung. Additionally, Vandetanib reduced activation of ERK1/2 and AKT and increased tumor cell apoptosis.	Clin Cancer Res. 2014 Apr 15;20(8):2115-25.
Nude mice	NSCLC xenograft models	Oral	50 mg/kg	Daily	Vandetanib significantly inhibited tumor growth in the HCC827 xenograft model, even showing complete tumor regression in larger tumors. In the HCC827-T790M model, vandetanib delayed the emergence of resistance. In the A549 model, vandetanib and bevacizumab/erlotinib combination therapy were more effective than erlotinib or bevacizumab alone. In the H1975 model, both vandetanib and bevacizumab significantly inhibited tumor growth.	Clin Cancer Res. 2009 May 15;15(10):3484-94.
Mice	MYCN/AlkF1178L neuroblastoma model	Oral	30 mg/kg	Daily treatment	To evaluate the inhibitory effect of the combination of crizotinib and vandetanib on MYCN/AlkF1178L neuroblastoma, the results showed that the combination therapy was more effective than crizotinib alone, significantly inhibiting tumor growth and prolonging the survival of mice.	Oncogene. 2018 Mar;37(11):1417-1429.

细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源

201T	2.5 μM	Function Assay	48 h	inhibits phospho-MAPK following EGF	22258476
201T	1/5/10 μM	Function Assay	48 h	blocks the phosphorylation of Akt induced by VEGFC	22258476
211H		Growth Inhibition Assay	72 h	IC50=2.2 μM	18364248
273T	2.5 μM	Function Assay	48 h	inhibits phospho-MAPK following EGF	22258476
8505C		Growth Inhibition Assay	72 h	IC50=7.56 ± 1.13 μM	21220477
A-431		Growth Inhibition Assay	72 h	GI50=2.4 ± 0.3 μM	24681205
A549	2.5 μM	Function Assay	48 h	inhibits phospho-MAPK following EGF	22258476
ACC2	0-10 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	18698025
ACC2	0-10 μM	Apoptosisi Assay	72 h	induces apoptosis dose dependently	18698025
ACC3	0-10 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	18698025
ACC3	0-10 μM	Apoptosisi Assay	72 h	induces apoptosis dose dependently	18698025
ACCM	0-10 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	18698025
ACCM	0-10 μM	Apoptosisi Assay	72 h	induces apoptosis dose dependently	18698025
C643		Growth Inhibition Assay	72 h	IC50=3.65 ± 1.22 μM	21220477
C666-1	0.1-25.6 μM	Growth Inhibition Assay	48 h	IC50=23.4 μM	17631646
C666-1	0.1-25.6 μM	Growth Inhibition Assay	72 h	IC50=4.86 μM	17631646
C666-1	6 μM	Function Assay	24 h	delays G0/G1 cell cycle progression	17631646
CNE-1	0.1-25.6 μM	Growth Inhibition Assay	48 h	IC50=3.6 μM	17631646
CNE-1	0.1-25.6 μM	Growth Inhibition Assay	72 h	IC50=2.3 μM	17631646
CNE-1	6 μM	Function Assay	24 h	delays G0/G1 cell cycle progression	17631646
CNE-2	0.1-25.6 μM	Growth Inhibition Assay	48 h	IC50=6.2 μM	17631646
CNE-2	0.1-25.6 μM	Growth Inhibition Assay	72 h	IC50=3.6 μM	17631646
CNE-2	6 μM	Function Assay	24 h	delays G0/G1 cell cycle progression	17631646
CRL1749	0-20 μM	Growth Inhibition Assay	24 h	inhibits cell growth in a dose dependent manner	19220256
EHMES-1		Growth Inhibition Assay	72 h	IC50=10.6 μM	18364248
EHMES-10		Growth Inhibition Assay	72 h	IC50=0.3 μM	18364248
H1650		Growth Inhibition Assay		IC50=3.5±1.2 μM	23274758
H2052		Growth Inhibition Assay		IC50=1.07±0.04 μM	21970874
H2052		Growth Inhibition Assay	72 h	IC50=8.0 μM	18364248
H2452		Growth Inhibition Assay		IC50=3.52±1.13 μM	21970874
H2452		Growth Inhibition Assay	72 h	IC50=5.5 μM	18364248
H28		Growth Inhibition Assay		IC50=0.32±0.07 μM	21970874
H28		Growth Inhibition Assay	72 h	IC50=1.8 μM	18364248
HAK1-B	1/5/10 μM	Function Assay	1 h	suppresses EGFR phosphorylation	22611027
HMEpC	1 nM-100 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	24138843
HT1376	0-20 μM	Growth Inhibition Assay	24 h	inhibits cell growth in a dose dependent manner	19220256
HTB3	0-20 μM	Growth Inhibition Assay	24 h	inhibits cell growth in a dose dependent manner	19220256
HTB9	0-20 μM	Growth Inhibition Assay	24 h	inhibits cell growth in a dose dependent manner	19220256
Hth104		Growth Inhibition Assay	72 h	IC50=±16.98 ± NA μM	21220477
Hth7		Growth Inhibition Assay	72 h	IC50=9.66 ± 0.38 μM	21220477
Hth74		Growth Inhibition Assay	72 h	IC50=8.56 ± 1.01 μM	21220477
Hth83		Growth Inhibition Assay	72 h	IC50=3.30 ± 0.66 μM	21220477
HuH-7		Growth Inhibition Assay	72 h	IC50 = 9.4 μmol/L	22611027
HUVECs		Growth Inhibition Assay	72 h	IC50 = 7.1 μmol/L	22611027
HUVECs	1/5/10 μM	Function Assay	1 h	significantly inhibits VEGFR-2 phosphorylation	22611027
J82	0-20 μM	Growth Inhibition Assay	24 h	inhibits cell growth in a dose dependent manner	19220256
Jurkat		Growth Inhibition Assay	72 h	GI50=1.5 ± 0.2 μM	24681205
K-562		Growth Inhibition Assay	72 h	GI50=1.8 ± 0.1 μM	24681205
KYN-2		Growth Inhibition Assay	72 h	IC50 = 8.1 μmol/L	22611027
MCF-7	1 nM-100 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	24138843
MDA-MB-231	1 nM-100 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	24138843
MDA-MB-468	1 nM-100 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	24138843
MSTO-211H		Growth Inhibition Assay		IC50=1.42±0.03 μM	21970874
NCTC-2544		Growth Inhibition Assay	72 h	GI50=4.6 ± 0.3 μM	24681205
PCI-15B	0-6 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	22307735
PCI-15B	0-10 μM	Function Assay	24 h	inhibits the activation of the EGFR tyrosine kinase and also decreases the expression of phosphorylated forms of the downstream signaling elements, STAT3 and MAPK	22307735
PCI-15B	1 μM	Function Assay	24 h	downregulates VEGF production	22307735
PCI-15B		Invasion Assay	24 h	EC50=558 nM	22307735
PCI-37A	0-6 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	22307735
PCI-37A	1 μM	Function Assay	24 h	downregulates VEGF production	22307735
PCI-37A		Invasion Assay	24 h	EC50=1695 nM	22307735
PCI-37B	0-6 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	22307735
PCI-37B		Invasion Assay	24 h	EC50=1726 nM	22307735
RT4	0-20 μM	Growth Inhibition Assay	24 h	inhibits cell growth in a dose dependent manner	19220256
SCC-25	0-6 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	22307735
SCC-25		Invasion Assay	24 h	EC50=10 nM	22307735
SH-SY5Y	0.625-20 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	24399074
SH-SY5Y	5/10/20 μM	Apoptosisi Assay	48 h	induces apoptosis dose dependently	24399074
SH-SY5Y	5/10/20 μM	Function Assay	48 h	induces G1 phase cell cycle arrest	24399074
SH-SY5Y	1/5/10 μM	Function Assay	48 h	inhibits RET phosphorylation	24399074
SH-SY5Y	5/10 μM	Function Assay	48 h	inhibits human NB cell migration	24399074
SH-SY5Y	5/10 μM	Function Assay	48 h	inhibits human NB cell invasion	24399074
SH-SY5Y	5 μM	Function Assay	24/48/72 h	suppresses the expression of CXCR4 and MMP14 mRNA	24399074
SH-SY5Y	5 μM	Function Assay	48/72 h	suppresses expression of the CXCR4 and MMP14 protein	24399074
SK-N-SH	0.625-20 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	24399074
SK-N-SH	5/10/20 μM	Apoptosisi Assay	48 h	induces apoptosis dose dependently	24399074
SK-N-SH	5/10/20 μM	Function Assay	48 h	induces G1 phase cell cycle arrest	24399074
SK-N-SH	1/5/10 μM	Function Assay	48 h	inhibits RET phosphorylation	24399074
SK-N-SH	5/10 μM	Function Assay	48 h	inhibits human NB cell migration	24399074
SK-N-SH	5/10 μM	Function Assay	48 h	inhibits human NB cell invasion	24399074
SK-N-SH	5 μM	Function Assay	24/48/72 h	suppresses the expression of CXCR4 and MMP14 mRNA	24399074
SK-N-SH	5 μM	Function Assay	48/72 h	suppresses expression of the CXCR4 and MMP14 protein	24399074
SN179	500 nM	Function Assay	16 h	increases CXCR4 expression significantly	25676691
SN179	500 nM	Function Assay	16 h	enhances the CXCL12 directed migration	25676691
SN179	500 nM	Function Assay	16 h	increases basal migration	25676691
SN186	500 nM	Function Assay	16 h	increases CXCR4 expression significantly	25676691
SUP	0-20 μM	Growth Inhibition Assay	24 h	inhibits cell growth in a dose dependent manner	19220256
SW1736		Growth Inhibition Assay	72 h	IC50=9.05 ± 0.55 μM	21220477
T24	0-20 μM	Growth Inhibition Assay	24 h	inhibits cell growth in a dose dependent manner	19220256
T-47-D	1 nM-100 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	24138843
U251	2/4/8 μℳ	Function Assay	6/12/24 h	increases the LC3-II level in a time-dependent and dose-dependent manner	23799852
U251	4 μℳ	Function Assay	2/6/12 h	suppresses basal levels of phosphorylation of S6 (S235/236), 4E-BP1 (T37/46), and Akt (S473) in a time-dependent manner	23799852
U87MG	2/4/8 μℳ	Function Assay	6/12/24 h	increases the LC3-II level in a time-dependent and dose-dependent manner	23799852
U87MG	4 μℳ	Function Assay	2/6/12 h	suppresses basal levels of phosphorylation of S6 (S235/236), 4E-BP1 (T37/46), and Akt (S473) in a time-dependent manner	23799852
UM-22A	0-6 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	22307735
UM-22A	0-10 μM	Function Assay	24 h	inhibits the activation of the EGFR tyrosine kinase and also decreases the expression of phosphorylated forms of the downstream signaling elements, STAT3 and MAPK	22307735
UM-22A	1 μM	Function Assay	24 h	downregulates VEGF production	22307735
UM-22A		Invasion Assay	24 h	EC50=0.3 nM	22307735
UM-22B	0-6 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	22307735
UM-22B	0-10 μM	Function Assay	24 h	inhibits the activation of the EGFR tyrosine kinase and also decreases the expression of phosphorylated forms of the downstream signaling elements, STAT3 and MAPK	22307735
UM-22B		Invasion Assay	24 h	EC50=2424 nM	22307735
ZR-75-1	1 nM-100 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	24138843

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02142036	Metastatic Cancer	Phase 2	Active, not recruiting	January 2022	Norway ... 展开 >> Akershus University Hospital Lillestrøm, Norway, 1478 The Norwegian Radium Hospital Oslo, Norway, 0379 收起 <<
NCT03413176	-		Completed	-	France ... 展开 >> AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM. Paris, France, 75013 收起 <<
NCT02788201	Urothelial Carcinoma ... 展开 >> Bladder Cancer Urinary Bladder Neoplasms 收起 <<	Phase 2	Recruiting	July 1, 2020	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT00499850	Advanced Colorectal Carcinoma	Phase 1	Completed	-	Australia ... 展开 >> Research Site East Melbourne, Australia Research Site Footscray, Australia Research Site Heidelberg, Australia Research Site Parkville, Australia 收起 <<
NCT02117167	Non-small Cell Lung Cancer Met... 展开 >>astatic 收起 <<	Phase 2	Recruiting	February 2022	France ... 展开 >> Centre Hospitalier Henri Duffau Recruiting Avignon, France Contact: Nicolas CLOAREC, MD nicolas.cloarec@ch-avignon.fr Principal Investigator: Nicolas CLOAREC, MD Centre Hospitalier Universitaire de Besancon - Hopital Jean Minjoz Recruiting Besancon, France Contact: Virginie WESTEEL, MD virginie.westeel@univ.fcomte.fr Principal Investigator: Virginie WESTEEL, MD Hôpital Avicenne Recruiting Bobigny, France Contact: Boris DUCHEMANN, MD boris.duchemann@aphp.fr Principal Investigator: Boris DUCHEMANN, MD Institut Bergonié Recruiting Bordeaux, France Contact: François Chomy, MD f.chomy@bordeaux.unicancer.fr Principal Investigator: François Chomy, MD Hôpital Ambroise Paré Recruiting Boulogne Billancourt, France Contact: Etienne GIROUX LEPRIEUR, MD etienne.giroux-leprieur@aphp.fr Principal Investigator: Etienne GIROUX LEPRIEUR, MD Hospices Civils de Lyon- Hôpital Louis Pradel Recruiting Bron, France Contact: Nicolas Girard, MD nicolas.girard@chu-lyon.fr Principal Investigator: Nicolas Girard, MD Centre François Baclesse Recruiting Caen, France Contact: Radj Gervais, MD r.gervais@baclesse.unicancer.fr Principal Investigator: Radj Gervais, MD CHU Caen Recruiting Caen, France Contact: Gérard Zalcman, MD zalcman-g@chu-caen.fr Principal Investigator: Gérard Zalcman, MD Chu de Caen - Hopital Cote de Nacre Recruiting Caen, France Contact: Jeannick MADELAINE, MD madelaine-j@chu-caen.fr Principal Investigator: Jeannick MADELAINE, MD Hôpital Louis Pasteur Recruiting Chartres, France Contact: Claire Lethrosne, MD clethrosne@ch-chartres.fr Principal Investigator: Claire Lethrosne, MD centre Jean Perrin Recruiting Clermont-Ferrand, France Contact: Xavier Durando, MD xavier.durando@cjp.fr Principal Investigator: Xavier Durando, MD CHU Clermont Ferrand - Hôpital Gabriel Montpied Recruiting Clermont-Ferrand, France Contact: Henri Janicot, MD hjanicot@chu-clermontferrand.fr Principal Investigator: Henri Janicot, MD Hopitaux Civils de Colmar Recruiting Colmar, France Contact: Lionel MOREAU, MD lionel.moreau@ch-colmar.fr Principal Investigator: Lionel MOREAU, MD Centre Hopsitalier Intercommunal de Créteil Recruiting Créteil, France Contact: Isabelle Monnet, MD isabelle.monnet@chicreteil.fr Principal Investigator: Isabelle Monnet, MD Centre Georges François Leclerc Recruiting Dijon, France Contact: Bruno Coudert, MD bcoudert@cgfl.fr Principal Investigator: Bruno Coudert, MD CHU Grenoble Recruiting Grenoble, France Contact: Denis Moro-Sibilot, MD Dmoro-Sibilot@chu-grenoble.fr Principal Investigator: Denis Moro-Sibilot, MD Chd Vendee Recruiting La Roche Sur Yon, France Contact: Tifenn L'HARIDON, MD Principal Investigator: Tifenn L'HARIDON, MD CH du Mans Recruiting Le Mans, France Contact: Olivier Molinier, MD omolinier@ch-lemans.fr Principal Investigator: Olivier Molinier, MD Centre Oscar Lambret Recruiting Lille, France Contact: Eric Dansin, MD e-dansin@o-lambret.fr Principal Investigator: Eric Dansin, MD CHRU de Lille Recruiting Lille, France Contact: Alexis Cortot, MD Alexis.CORTOT@CHRU-LILLE.FR Principal Investigator: Alexis Cortot, MD Centre Léon Bérard Recruiting Lyon, France Contact: Maurice Pérol, MD maurice.perol@lyon.unicancer.fr Principal Investigator: Maurice Pérol, MD Hôpital Nord Recruiting Marseille, France Contact: Fabrice Barlesi, MD fabrice.barlesi@ap-hm.fr Principal Investigator: Fabrice Barlési, MD Institut Paoli Calmettes Recruiting Marseille, France Contact: Anne MADROSZYK, MD madroszyka@ipc.unicancer.fr Principal Investigator: Anne MADROSZYK, MD Institut de cancérologie de l'Ouest Recruiting Nantes, France Contact: Jaafar Bennouna, MD jaafar.bennouna@ico.unicancer.fr Principal Investigator: Jaafar Bennouna, MD Centre Antoine Lacassagne Recruiting Nice, France Contact: Josiane OTTO, MD josiane.otto@nice.unicancer.fr Principal Investigator: Josiane OTTO, MD Chr Orleans Recruiting Orleans, France Contact: Hugues MOREL, MD hugues.morel@chr-orleans.fr Contact: , MD Principal Investigator: Hugues MOREL AH-HP Hôpital Saint Louis Recruiting Paris, France Contact: Damien Pouessel, MD damien.pouessel@sls.aphp.fr Principal Investigator: Damien Pouessel, MD AP-HP Hôpital Cochin Recruiting Paris, France Contact: Jeanne Chapron, MD jeanne.chapron@cch.aphp.fr Principal Investigator: Jeanne Chapron, MD AP-HP Hôpital Européen Georges Pompidou Withdrawn Paris, France AP-HP Hôpital Tenon Recruiting Paris, France Contact: Marie Wislez, MD marie.wislez@tnn.aphp.fr Principal Investigator: Marie Wislez, MD Institut Curie Recruiting Paris, France Contact: Catherine Daniel, MD catherine.daniel@curie.fr Principal Investigator: Catherine Daniel, MD Centre Hospitalier de Pau Recruiting PAU, France Contact: Aldo RENAULT, MD aldo.renault@ch-pau.fr Principal Investigator: Aldo RENAULT, MD Centre Hospitalier Lyon Sud Recruiting Pierre Bénite, France Contact: Jean-Pierre Souquet, MD pierre-jean.souquet@chu-lyon.fr Principal Investigator: Jean-Pierre Souquet, MD CHR Pontchailloux Withdrawn Rennes, France Chru Strasbourg - Nouvel Hopital Civil Recruiting Strasbourg, France Contact: Philippe BARTHELEMY, MD Principal Investigator: Philippe BARTHELEMY, MD CHI de Toulon - Hôpital Sainte-Musse Recruiting Toulon, France Contact: Xavier TCHIKNAVORIAN, MD Principal Investigator: Xavier TCHIKNAVORIAN, MD CHU Toulouse -Hôpital Larrey Recruiting Toulouse, France Contact: Julien Mazières, MD mazieres.j@chu-toulouse.fr Principal Investigator: Julien Mazières, MD Hôpital Bretonneau Recruiting Tours, France Contact: Eric Pichon, MD e.pichon@chu-tours.fr Principal Investigator: Eric Pichon, MD Gustave Roussy Recruiting Villejuif, France Contact: Benjamin Besse, MD Benjamin.BESSE@gustaveroussy.fr Principal Investigator: Benjamin Besse, MD Sub-Investigator: Jean-Charles Soria, MD 收起 <<
NCT02299999	Metastatic Breast Cancer	Phase 2	Recruiting	December 2022	France ... 展开 >> Institut de Cancérologie de l'Ouest/Paul Papin Recruiting Angers, France Contact: Mario CAMPONE, MD mario.campone@ico.unicancer.fr Principal Investigator: Mario CAMPONE, MD Institut Sainte-Catherine Recruiting Avignon, France Contact: Alice Mege, MD a.mege@isc84.org Principal Investigator: Alice Mege, MD Polyclinique Bordeaux Nord Aquitaine Recruiting Bordeaux, France, 33077 Contact: Nadine DOHOLLOU, MD n.dohollou@bordeauxnord.com Contact: Nadine DOHOLLOU, MD Institut Bergonié Recruiting Bordeaux, France Contact: Hervé Bonnefoi, MD h.bonnefoi@bordeaux.unicancer.fr Principal Investigator: Hervé Bonnefoi, MD Centre François Baclesse Recruiting Caen, France Contact: Christelle Lévy, MD c.levy@baclesse.unicancer.fr Principal Investigator: Christelle Lévy, MD Centre Jean Perrin Recruiting Clermont-Ferrand, France Contact: Marie-Ange Mouret Reynier, MD marie-ange.mouret-reynier@cjp.fr Principal Investigator: Marie-Ange Mouret Reynier, MD Ch Alpes Leman Not yet recruiting Contamine Sur Arve, France, 74130 Contact: Carol ALLIOT, MD calliot@ch-alpes-leman.fr Contact: Carol ALLIOT, MD Centre Georges François Leclerc Recruiting Dijon, France, 21079 Contact: Nicolas Isambert, MD nisambert@cgfl.fr Principal Investigator: Nicolas Isambert, MD Chd Vendee Recruiting La Roche-sur-Yon, France, 85925 Contact: Tifenn L'Haridon, MD tifenn.lharidon@chd-vendee.fr Contact: Tifenn L'Haridon, MD Centre Oscar Lambret Recruiting Lille, France Contact: Nuria KOTECKI, MD Principal Investigator: Nuria KOTECKI, MD Chu Dupuytren Not yet recruiting Limoges, France, 87000 Contact: Laurence VENAT-BOUVET, MD laurence.venat-bouvet@chu-limoges.fr Contact: Laurence VENAT-BOUVET, MD Hopital Privé Jean Mermoz Not yet recruiting Lyon, France, 69008 Contact: Olfa DERBEL, MD o.derbelmermoz@gmail.com Contact: Olfa DERBEL, MD Centre Hospitalier Lyon Sud Recruiting Lyon, France Contact: Benoit You, MD Principal Investigator: Benoit You, MD Centre Léon Bérard Recruiting Lyon, France Contact: Thomas Bachelot, MD thomas.bachelot@lyon.unicancer.fr Principal Investigator: Thomas Bachelot, MD Institut Paoli Calmettes Recruiting Marseille, France Contact: Anthony Gonçalves, MD goncalvesa@ipc.unicancer.fr Principal Investigator: Anthony Gonçalves, MD Institut Régional du Cancer Montpellier Val d'Aurelle Recruiting Montpellier, France Contact: William Jacot, MD william.jacot@icm.unicancer.fr Principal Investigator: William Jacot, MD Centre Alexis Vautrin Recruiting Nancy, France Contact: Elisabeth Luporsi, MD e.luporsi@nancy.unicancer.fr Principal Investigator: Elisabeth Luporsi, MD Institut de Cancérologie de l'Ouest/ René Gauducheau Recruiting Nantes, France Contact: Mario Campone, MD mario.campone@ico.unicancer.fr Principal Investigator: Mario Campone, MD Centre Antoine Lacassagne Recruiting Nice, France Contact: Jean-Marc Ferrero, MD jean-marc.ferrero@nice.unicancer.fr Principal Investigator: Jean-Marc Ferrero, MD Institut Curie Recruiting Paris, France Contact: Marie-Paule Sablin, MD mariepaule.sablin@curie.fr Principal Investigator: Marie-Paule Sablin, MD Centre Eugène Marquis Recruiting Rennes, France Contact: Claudia Lefeuvre-Plesse, MD c.lefeuvre@rennes.unicancer.fr Principal Investigator: Claudia Lefeuvre-Plesse, MD Centre Henri Becquerel Recruiting Rouen, France Contact: Jean-Christophe Théry, MD Principal Investigator: Jean-Christophe Théry, MD Institut Curie Recruiting Saint-Cloud, France Contact: Florence COUSSY, MD florence.coussy@curie.fr Principal Investigator: Florence COUSSY, MD Hopitaux Universitaire de Strasbourg - Hopital Civil Recruiting Strasbourg, France Contact: Philippe BARTHELEMY, MD philippe.barthelemy@chru-strasbourg.fr Principal Investigator: Philippe BARTHELEMY, MD Hopitaux Du Leman Recruiting Thonon-les-Bains, France, 74200 Contact: Francesco DEL PIANO, MD f-delpiano@ch-hopitauxduleman.fr Contact: Francesco DEL PIANO, MD Institut Claudius Regaud Recruiting Toulouse, France Contact: Florence Dalenc, MD dalenc.florence@iuct-oncopole.fr Principal Investigator: Florence Dalenc, MD Gustave Roussy Recruiting Villejuif, France Contact: Monica Arnedos, MD Monica.ARNEDOS@gustaveroussy.fr Principal Investigator: Monica Arnedos, MD Sub-Investigator: Fabrice André, MD 收起 <<
NCT00496509	Colorectal Cancer	Phase 1	Completed	-	Germany ... 展开 >> Research Site Freiberg, Germany 收起 <<
NCT00290537	-		Terminated(Accrual was subopti... 展开 >>mal and increasing the number of patients was not feasible.) 收起 <<	-	-
NCT01838642	Thyroid Neoplasms	Phase 2	Terminated(Recruiting halted p... 展开 >>rematurely and will not resume. New study to open soon.) 收起 <<	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01838642	-		Terminated(Recruiting halted p... 展开 >>rematurely and will not resume. New study to open soon.) 收起 <<	-	-
NCT02638428	Relapsed Pediatric Solid Tumor... 展开 >> Refractory Pediatric Solid Tumor Relapsed Pediatric AML Refractory Pediatric AML 收起 <<	Phase 2	Recruiting	December 2023	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Ki Woong Sung 82-2-3410-3529 kwsped@skku.edu Principal Investigator: Ki Woong Sung 收起 <<
NCT00290537	Lung Cancer	Phase 2	Terminated(Accrual was subopti... 展开 >>mal and increasing the number of patients was not feasible.) 收起 <<	-	United States, Texas ... 展开 >> University of Texas M.D.Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00533169	Neuroblastoma	Phase 1	Terminated(Lack of enrollment.... 展开 >>) 收起 <<	-	United States, Texas ... 展开 >> U.T.M.D. Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00252746	Non Small Cell Lung Carcinoma	Phase 2	Completed	-	Japan ... 展开 >> Research Site Matsuyama, Ehime, Japan Research Site Isehara, Kanagawa, Japan Research Site Osakasayama, Osaka, Japan Research Site Toyonaka, Osaka, Japan Research Site Sunto-gun, Shizuoka, Japan Research Site Okayama, Japan Research Site Tokyo, Japan 收起 <<
NCT02013089	Gastrointestinal Cancers	Not Applicable	Unknown	December 2017	China, Guangdong ... 展开 >> Gastrointestinal Hospital, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510655 Contact: Yanghong Deng, PhD 008613925106525 13925106525@163.com Principal Investigator: Yanhong Deng, PhD 收起 <<
NCT00066313	Lung Cancer	Phase 2	Completed	-	Canada, Alberta ... 展开 >> Tom Baker Cancer Centre - Calgary Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute at University of Alberta Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia British Columbia Cancer Agency - Centre for the Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 Fraser/Valley Cancer Centre at British Columbia Cancer Agency Surrey, British Columbia, Canada, V3V 1Z2 British Columbia Cancer Agency - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, New Brunswick Moncton Hospital Moncton, New Brunswick, Canada, E1C 6ZB Saint John Regional Hospital Saint John, New Brunswick, Canada, E2L 4L2 Canada, Ontario Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston General Hospital Kingston, Ontario, Canada, K7L 5P9 Ottawa Hospital Regional Cancer Centre - General Campus Ottawa, Ontario, Canada, K1H 8L6 St. Catharines General Hospital at Niagara Health System St. Catharines, Ontario, Canada, L2R 5K3 Northwestern Ontario Regional Cancer Care at Thunder Bay Regional Health Sciences Centre Thunder Bay, Ontario, Canada, P7B 6V4 Toronto East General Hospital Toronto, Ontario, Canada, M4C 3E7 Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 Mount Sinai Hospital - Toronto Toronto, Ontario, Canada, M5G 1X5 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Windsor Regional Cancer Centre at Windsor Regional Hospital Windsor, Ontario, Canada, N8W 2X3 Canada, Quebec Hopital Notre- Dame du CHUM Montreal, Quebec, Canada, H2L 4M1 McGill Cancer Centre at McGill University Montreal, Quebec, Canada, H2W 1S6 L'Hopital Laval Ste-Foy, Quebec, Canada, G1V 4G5 Canada, Saskatchewan Saskatoon Cancer Centre at the University of Saskatchewan Saskatoon, Saskatchewan, Canada, S7N 4H4 收起 <<
NCT00410189	Lung Cancer	Phase 2	Completed	-	United States, Texas ... 展开 >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00745732	Non-Small Cell Lung Cancer	Phase 1	Terminated(Sponsor withdrew su... 展开 >>pport.) 收起 <<	-	United States, Texas ... 展开 >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00659438	Prostate Cancer	Phase 2	Completed	-	France ... 展开 >> Research Site Bordeaux Cedex, France Research Site Creteil, France Research Site Paris, France Research Site Reims Cedex, France Research Site Villejuif, France 收起 <<
NCT02239952	Cancer High-g... 展开 >>rade Glioma 收起 <<	Not Applicable	Recruiting	January 2019	Netherlands ... 展开 >> VU University Medical Center Recruiting Amsterdam, Noord-Holland, Netherlands, 1081 HV Contact: H.M.W Verheul, MD, PhD +31 (0)20 4444321 h.verheul@vumc.nl 收起 <<
NCT00613054	Glioblastoma ... 展开 >>Gliosarcoma 收起 <<	Phase 1	Completed	-	United States, North Carolina ... 展开 >> Duke University Health System Durham, North Carolina, United States, 27710 收起 <<
NCT00358956	Thyroid Cancer	Phase 2	Completed	-	United States, Arkansas ... 展开 >> Research Site Little Rock, Arkansas, United States United States, Massachusetts Research Site Boston, Massachusetts, United States Australia Research Site St Leonards, Australia Canada, Quebec Research Site Sherbrooke, Quebec, Canada Italy Research Site Pisa, Italy Netherlands Research Site Utrecht, Netherlands Romania Research Site Bucharest, Romania Spain Research Site Madrid, Spain Switzerland Research Site Basel, Switzerland 收起 <<
NCT00358956	-		Completed	-	-
NCT00496665	Metastatic Breast Cancer	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Massachusetts General Hospital Boston, Massachusetts, United States, 02215 收起 <<
NCT00410189	-		Completed	-	-
NCT00404924	Non-Small-Cell Lung Carcinoma	Phase 3	Completed	-	-
NCT00659438	-		Completed	-	-
NCT00811369	Metastatic Breast Cancer	Phase 2	Completed	-	Canada, Alberta ... 展开 >> Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia British Columbia Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Nova Scotia QE II Health Sciences Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Grand River Regional Cancer Centre Kitchener, Ontario, Canada, N2G 1G3 RSM Durham Regional Cancer Centre Oshawa, Ontario, Canada, L1G 2B9 Ottawa Hospital Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 Regional Cancer Program of the Hôpital régional de Sudbury Regional Hospital Sudbury, Ontario, Canada, P3E 5J1 Odette Cancer Centre - Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 St. Michael's Hospital Toronto, Ontario, Canada, M5B 1W8 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Centre Hospitalier De L'Universite De Montreal - Hotel Dieu Montreal, Quebec, Canada, H2W 1T7 Canada, Saskatchewan Saskatoon Cancer Centre Saskatoon, Saskatchewan, Canada, S7N 4H4 收起 <<
NCT00454116	Colorectal Cancer	Phase 2	Completed	-	United States, Michigan ... 展开 >> Research Site Ann Arbor, Michigan, United States United States, New York Research Site New York, New York, United States United States, Tennessee Research Site Nashville, Tennessee, United States United States, Utah Research Site Salt Lake City, Utah, United States Argentina Research Site Buenos Aires, Argentina Research Site Ramos Mejia, Argentina Research Site Rosario, Argentina Research Site Santa Fe, Argentina Research Site Vicente Lopez, Argentina Korea, Republic of Research Site Seoul, Korea, Republic of Norway Research Site Bergen, Norway Research Site Oslo, Norway Research Site Stavanger, Norway Spain Research Site A Coruna, Spain Research Site Barcelona, Spain Research Site Jaen, Spain Research Site Lerida, Spain Research Site Lleida, Spain United Kingdom Research site Belfast, Northern Ireland, United Kingdom Research Site Aberdeen, United Kingdom Research Site Leicester, United Kingdom Research Site Manchester, United Kingdom 收起 <<
NCT00454116	-		Completed	-	-
NCT00364351	Non Small Cell Lung Cancer	Phase 3	Completed	-	-
NCT00498797	Prostate Cancer ... 展开 >> Metastatic Hormone Refractory 收起 <<	Phase 2	Completed	-	Brazil ... 展开 >> Research site Rio de Janeiro, Brazil Research Site Sao Paulo, Brazil Germany Research Site Hamburg, Germany Research Site Hannover, Germany Research Site Kassel, Germany Research Site Tubingen, Germany Hungary Research Site Budapest, Hungary South Africa Research Site Bloemfontein, South Africa Research Site Cape Town, South Africa Sweden Research Site Umea, Sweden Research Site Uppsala, Sweden 收起 <<
NCT03630120	Thyroid Cancer ... 展开 >> Thyroid Cancer, Medullary Differentiated Thyroid Cancer Papillary Thyroid Cancer Follicular Thyroid Cancer Poorly Differentiated Thyroid Gland Carcinoma 收起 <<	Phase 2	Recruiting	December 2023	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 收起 <<
NCT00364351	-		Completed	-	-
NCT00494481	-		Completed	-	-
NCT00404924	-		Completed	-	-
NCT00494481	Advanced Breast Cancer	Phase 2	Completed	-	Hungary ... 展开 >> Research Site Budapest, Hungary Research Site Pécs, Hungary South Africa Research SIte Bloemfontein, South Africa Research Site Cape Town, South Africa Research Site Observatory, South Africa Spain Research Site Baracaldo, Spain Research SIte Lérida, Spain Research Site Zaragoza, Spain Sweden Research Site Umeå, Sweden Research Site Uppsala, Sweden Research Site Västerås, Sweden Taiwan Research Site Taipei, Taiwan 收起 <<
NCT00410761	Thyroid Cancer	Phase 3	Active, not recruiting	December 31, 2019	-
NCT00410761	-		Active, not recruiting	-	-
NCT00450138	Head and Neck Cancer	Phase 1	Completed	-	United States, Colorado ... 展开 >> Research Site Denver, Colorado, United States United States, Illinois Research Site Chicago, Illinois, United States United States, Texas Research Site Dallas, Texas, United States Research Site Houston, Texas, United States 收起 <<
NCT00681798	Pancreatic Cancer	Phase 1	Completed	-	Switzerland ... 展开 >> Research Site St Gallen, SG, Switzerland Research Site Bellinzona, Switzerland 收起 <<
NCT00507091	Metastatic Co... 展开 >>lorectal Adenocarcinoma 收起 <<	Phase 1	Completed	-	Belgium ... 展开 >> Research Site Gent, Belgium United Kingdom Research Site Belfast, United Kingdom Research Site Manchester, United Kingdom 收起 <<
NCT00312377	Non-small Cell Lung Cancer ... 展开 >> Lung Cancer 收起 <<	Phase 3	Completed	-	-
NCT00503711	Advanced Solid, Malignant Tumo... 展开 >>rs 收起 <<	Phase 1	Completed	-	China ... 展开 >> Research Site Guangzhou, China 收起 <<
NCT00459121	Lung Cancer	Phase 2	Terminated	-	United States, Michigan ... 展开 >> Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201-1379 收起 <<
NCT00312377	-		Completed	-	-
NCT00418886	Non Small Cell Lung Cancer ... 展开 >> Lung Cancer 收起 <<	Phase 3	Active, not recruiting	December 2019	-
NCT00601614	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Withdrawn(no enrollment)	-	-
NCT00418886	-		Active, not recruiting	-	-
NCT00498797	-		Completed	-	-
NCT00686036	Prostate Cancer	Phase 2	Terminated(Slow recruitment)	-	Canada, Alberta ... 展开 >> Research Site Calgary, Alberta, Canada Research Site Edmonton, Alberta, Canada Canada, British Columbia Research Site Victoria, British Columbia, Canada Canada, Ontario Research Site Hamilton, Ontario, Canada Research Site Kingston, Ontario, Canada Research Site London, Ontario, Canada Research Site Toronto, Ontario, Canada Canada, Quebec Research Site Greenfield Park, Quebec, Canada Research Site Montreal, Quebec, Canada Research Site Sherbrooke, Quebec, Canada Canada Research Site Granby, Canada 收起 <<
NCT00459121	-		Terminated	-	-
NCT00686036	-		Terminated(Slow recruitment)	-	-
NCT00752986	Breast Cancer	Phase 2	Terminated	-	Italy ... 展开 >> Research Site Avellino, Italy Research Site Benevento, Italy Research Site Genova, Italy Research Site Milano, Italy Research Site Monserrato, Italy Research Site Napoli, Italy Research Site Palermo, Italy Research Site Prato, Italy Research Site Roma, Italy Research Site Trento, Italy Research Site Varese, Italy 收起 <<
NCT00506051	Carcinoma Non... 展开 >>-Small Cell Lung Lung Cancer 收起 <<	Phase 1	Completed	-	-
NCT00752986	-		Terminated	-	-
NCT00481845	Breast Cancer	Phase 2	Terminated(Low accrual)	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 收起 <<
NCT00937417	Breast Cancer ... 展开 >> Head and Neck Cancer Lung Cancer Prostate Cancer Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Withdrawn(Withdrawn because SW... 展开 >>OG no longer pursuing this study at this time) 收起 <<	September 2009	-
NCT00481845	-		Terminated(Low accrual)	-	-
NCT00734890	Lung Cancer L... 展开 >>ymphoma Lymphoproliferative Disorder Small Intestine Cancer Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda, Maryland, United States, 20892-1182 收起 <<
NCT00098345	Thyroid Cancer	Phase 2	Completed	-	United States, California ... 展开 >> Research Site San Francisco, California, United States United States, Connecticut Research Site New Haven, Connecticut, United States United States, New York Research Site New York, New York, United States United States, North Carolina Research Site Durham, North Carolina, United States United States, Texas Research Site Houston, Texas, United States France Research Site Villejuif Cedex, France 收起 <<
NCT01414426	Lip and Oral Cavity Squamous C... 展开 >>ell Carcinoma Oral Cavity Verrucous Carcinoma Precancerous Condition 收起 <<	Phase 2	Active, not recruiting	March 2018	United States, Illinois ... 展开 >> University of Chicago Chicago, Illinois, United States, 60637 收起 <<
NCT00508001	-		Completed	-	-
NCT00597116	Mesothelioma	Phase 2	Terminated(Recruitment stopped... 展开 >> according to early stopping rule (by protocol)) 收起 <<	-	Germany ... 展开 >> Research Site Essen, Germany Research Site Halle-Dolau, Germany Research Site Hamburg, Germany Research Site Heidelberg, Germany Switzerland Research Site Chur, Switzerland Research Site Zurich, Switzerland 收起 <<
NCT00732745	Adenocarcinoma of the Gastroes... 展开 >>ophageal Junction Esophageal Cancer 收起 <<	Phase 1	Terminated(Lost funding for Ph... 展开 >>ase II portion of study) 收起 <<	-	United States, Ohio ... 展开 >> Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 收起 <<
NCT00597116	-		Terminated(Recruitment stopped... 展开 >> according to early stopping rule (by protocol)) 收起 <<	-	-
NCT00508001	Carcinoma, Hepatocellular	Phase 2	Completed	-	Taiwan ... 展开 >> Research Site Tainan, Taiwan Research Site Taipei, Taiwan Research Site Taoyuan, Taiwan 收起 <<
NCT00753714	-		Completed	-	-
NCT00441142	Glioblastoma Multiforme ... 展开 >> Gliosarcoma 收起 <<	Phase 1 Phase 2	Active, not recruiting	January 2018	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber / Brigham and Women's Cancer Center Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232-1305 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908-4324 收起 <<
NCT00753675	Biliary Tract Cancer ... 展开 >> Gallbladder Cancer Cancer Of The Extrahepatic Bile Duct Ampullary Carcinoma 收起 <<	Phase 2	Completed	-	Italy ... 展开 >> Research Site Brescia, BS, Italy Research Site Firenze, FI, Italy Research Site Genova, GE, Italy Research Site Milano, Mi, Italy Research Site Palermo, PA, Italy Research Site Aviano, PN, Italy Research Site Parma, PR, Italy Research Site Reggio Emilia, RE, Italy Research Site Ancona, Italy Research Site Livorno, Italy Research Site Napoli, Italy Research Site Pisa, Italy Research Site Ravenna, Italy Research Site Rho, Italy Research Site Torino, Italy 收起 <<
NCT00441142	-		Active, not recruiting	-	-
NCT00807170	Non-small Cell Lung Cancer (NS... 展开 >>CLC) 收起 <<	Phase 1	Terminated(Very slow recruitme... 展开 >>nt) 收起 <<	-	Netherlands ... 展开 >> Research site Amsterdam, Netherlands Research site Groningen, Netherlands Research site Maastricht, Netherlands 收起 <<
NCT00777179	NSCLC	Phase 2	Completed	-	Korea, Republic of ... 展开 >> Research Site CheongJu, Republic of Korea, Korea, Republic of Research Site Gyeonggi-do, Republic of Korea, Korea, Republic of Research Site Gyeongsangnam-Do, Republic of Korea, Korea, Republic of Research Site Incheon, Republic of Korea, Korea, Republic of Research Site Seoul, Republic of Korea, Korea, Republic of 收起 <<
NCT00098345	-		Completed	-	-
NCT00500292	-		Completed	-	-
NCT00777179	-		Completed	-	-
NCT01757470	-		Completed	-	Canada, Quebec ... 展开 >> Research Site Montreal, Quebec, Canada 收起 <<
NCT02268734	-		Unknown	December 2014	Italy ... 展开 >> Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Recruiting Milano, Italy, 20133 Contact: Laura Locati, MD +39 022390 ext 2765 laura.locati@istitutotumori.mi.it Principal Investigator: Laura Locati, MD 收起 <<
NCT00753675	-		Completed	-	-
NCT00720083	Head and Neck Cancer	Phase 2	Terminated(Withdrawal of drug ... 展开 >>supply.) 收起 <<	-	-
NCT00720083	-		Terminated(Withdrawal of drug ... 展开 >>supply.) 收起 <<	-	-
NCT00667147	Solid Tumors	Phase 1	Completed	-	United States, California ... 展开 >> University of Southern California (U.S.C.)/ Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 收起 <<
NCT00500292	Colorectal Ca... 展开 >>ncer 收起 <<	Phase 2	Completed	-	France ... 展开 >> Research Site Lille Cedex, France Research Site Toulouse Cedex 9, France Hungary Research Site Budapest, Hungary Research Site Debrecen, Hungary Research Site Szeged, Hungary Korea, Republic of Research Site Seoul, Korea, Republic of Slovakia Research Site Bratislava, Slovakia Research Site Poprad, Slovakia Research Site Trnava, Slovakia Research Site Zilina, Slovakia Spain Research Site Hospitalet deLlobregat, Spain Research Site Oviedo, Spain Research Site Santander, Spain Taiwan Research Site Taipei, Taiwan Research Site Tao-Yuan, Taiwan 收起 <<
NCT00872989	Fallopian Tube Cancer ... 展开 >> Ovarian Cancer Primary Peritoneal Cavity Cancer 收起 <<	Phase 2	Completed	-	-
NCT00872989	-		Completed	-	-
NCT00822887	Malignant Gliomas	Phase 1	Completed	-	United States, Colorado ... 展开 >> University of Colorado Health Science Center Aurora, Colorado, United States, 80045 收起 <<
NCT00753714	Non Small Cell Lung Cancer	Phase 2	Completed	-	Italy ... 展开 >> Research Site Meldola, (fc), Italy Research Site Avellino, AV, Italy Research Site Bari, BA, Italy Research Site Treviglio, BG, Italy Research Site Bologna, BO, Italy Research Site Genova, GE, Italy Research Site Taormina, ME, Italy Research Site Milano, MI, Italy Research Site Perugia, PG, Italy Research Site Ravenna, RA, Italy Research Site Trento, TN, Italy Research Site Orbassano, TO, Italy Research Site Udine, UD, Italy Research Site Padova, Italy Research Site Roma, Italy 收起 <<
NCT00995007	-		Completed	-	-
NCT00687297	Lung Cancer N... 展开 >>on Small Cell Lung Cancer 收起 <<	Phase 2	Completed	-	-
NCT00683787	Gastric Cancer	Phase 2	Terminated(low accrual)	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263-0001 收起 <<
NCT00687297	-		Completed	-	-
NCT00995007	Glioblastoma Multiforme ... 展开 >> Gliosarcoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Mixed Oligoastrocytoma 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00880334	Transitional Cell Carcinoma ... 展开 >> Bladder Cancer 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00880334	-		Completed	-	-
NCT00532909	Anal, Colon, and Rectal Cancer... 展开 >>s Colorectal Neoplasms Colon/Rectal Cancer 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 收起 <<
NCT01372813	Advanced Clear Cell Renal Carc... 展开 >>inoma 收起 <<	Phase 2	Terminated(Terminated for insu... 展开 >>fficient accrual.) 收起 <<	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00537095	-		Active, not recruiting	-	-
NCT00757692	Prostate Cancer	Phase 2	Completed	-	Canada, British Columbia ... 展开 >> BC Cancer Agency - Centre for Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 收起 <<
NCT00683787	-		Terminated(low accrual)	-	-
NCT00862836	Ovarian Cancer	Phase 1 Phase 2	Terminated(Lack of efficacy)	-	Germany ... 展开 >> Research Site Ulm, Baden-Württemberg, Germany Research Site Wiesbaden, Hessen, Germany Research Site Essen, Nordrhein-Westfalen, Germany Research Site Kiel, Schleswig-Holstein, Germany Research Site Berlin, Germany 收起 <<
NCT00537095	Thyroid Neoplasms	Phase 2	Active, not recruiting	December 31, 2019	Belgium ... 展开 >> Research Site Brussels, Belgium Denmark Research Site Odense, Denmark France Research Site Angers Cedex 9, France Research Site Angers Cedex, France Research Site Bordeaux Cedex, France Research Site Caen Cedex 5, France Research Site Caen Cedex, France Research Site Lyon Cedex, France Research Site Lyon, France Research Site Marseille Cedex 9, France Research Site Marseille Cedex, France Research Site Paris Cedex 10, France Research Site Paris Cedex 13, France Research Site Paris, France Research Site Villejuif Cedex, France Research Site Villejuif, France Norway Research Site Oslo, Norway Spain Research Site L'Hospitalet de Llobregat, Spain Research Site Madrid, Spain Sweden Research Site Lund, Sweden Research Site Stockholm, Sweden Switzerland Research Site Bern, Switzerland 收起 <<
NCT01945762	-		Recruiting	September 2019	Belgium ... 展开 >> Research Site Active, not recruiting Brussels, Belgium France Research Site Active, not recruiting Bordeaux, France Research Site Terminated Lyon, France Research Site Recruiting Paris, France Research Site Recruiting Villejuif, France Germany Research Site Recruiting Augsburg, Germany Research Site Active, not recruiting Essen, Germany Research Site Active, not recruiting Heidelberg, Germany Research Site Active, not recruiting Munchen, Germany Italy Research Site Recruiting Catania, Italy Research Site Recruiting MIlano, Italy Research Site Active, not recruiting Milano, Italy Research Site Active, not recruiting Naples, Italy Research Site Recruiting Padova, Italy Research Site Recruiting Pisa, Italy Research Site Recruiting Siena, Italy Luxembourg Research Site Active, not recruiting Luxembourg, Luxembourg Netherlands Research Site Active, not recruiting Groningen, Netherlands Research Site Recruiting Leiden, Netherlands Spain Research Site Recruiting Barcelona, Spain Research Site Active, not recruiting Madrid, Spain Research Site Recruiting Madrid, Spain Research Site Active, not recruiting Oviedo, Spain Research Site Terminated Sevilla, Spain United Kingdom Research Site Terminated Glasgow, United Kingdom Research Site Recruiting London, United Kingdom Research Site Terminated London, United Kingdom Research Site Active, not recruiting Manchester, United Kingdom Research Site Active, not recruiting Sheffield, United Kingdom Research Site Recruiting Sutton, United Kingdom 收起 <<
NCT01372813	-		Terminated(Terminated for insu... 展开 >>fficient accrual.) 收起 <<	-	-
NCT00862836	-		Terminated(Lack of efficacy)	-	-
NCT00445549	-		Terminated(The study closed be... 展开 >>cause of inadequate early activity.) 收起 <<	-	-
NCT00445549	Ovarian Neoplasms ... 展开 >> Fallopian Tube Neoplasms Peritoneal Neoplasms 收起 <<	Phase 2	Terminated(The study closed be... 展开 >>cause of inadequate early activity.) 收起 <<	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01191892	Bladder Cancer ... 展开 >> Transitional Cell Cancer of the Renal Pelvis and Ureter Ureter Cancer Urethral Cancer 收起 <<	Phase 2	Unknown	December 2014	United Kingdom ... 展开 >> Beatson West of Scotland Cancer Centre Recruiting Glasgow, Scotland, United Kingdom, G12 0YN Contact: Contact Person 44-141-301-7095 Rob.Jones@ggc.scot.nhs.uk Wales Cancer Trials Unit Recruiting Cardiff, Wales, United Kingdom, CF11 9LJ Contact: Contact Person 44-29-2019-6800 Ayr Hospital Recruiting Ayr, United Kingdom, KA66DX Contact: Margaret McKernan 01563 825749 margaret.mckernan@aaaht.scot.nhs.uk Principal Investigator: Jawaher Ansari Royal Bournemouth General Hospital Recruiting Bournemouth, United Kingdom, BH7 7DW Contact: Susannah Brock susannah.brock@poole.nhs.uk Principal Investigator: Susannah Brock Queens Hospital Recruiting Burton upon Trent, United Kingdom, DE13 0RB Contact: Pugazhenthi Pattu 01332 340131 pugazhenthi.pattu@nhs.net Principal Investigator: Pugazhenthi Pattu Velindre Hospital Recruiting City and County of Cardiff, United Kingdom, CF142TL Contact: Dr Lester, Jason 44-2920 196159 jason.lester2@wales.nhs.uk Principal Investigator: Jason Lester Western General Hospital Recruiting Edinburgh, United Kingdom, EH4 2XU Contact: Duncan McLaren duncan.mclaren@luht.scot.nhs.uk Principal Investigator: Duncan McLaren Calderdale Royal Infirmary Recruiting Halifax, United Kingdom, HX30PW Contact: Lisa Gledhill 01484 342925 lisa.gledhill@cht.nhs.uk Principal Investigator: Ursula Hofmann Huddersfield Royal Infirmary Recruiting Huddersfield, United Kingdom, HD3 3EA Contact: Uschi Hofmann 0484 847299 uschi.hofmann@cht.nhs.uk Principal Investigator: Uschi Hofmann The Royal Lancaster Infirmary Recruiting Lancaster, United Kingdom, LA1 4RP Contact: Alison Birtle 01524 583219 alison.birtle@lhtr.nhs.uk Principal Investigator: Alison Birtle St. James's University Hospital Recruiting Leeds, United Kingdom, LS9 7TF Contact: Satinder Jagdev 0113 2067645 satinder.jagdev@leedsth.nhs.uk Principal Investigator: Satinder Jagdev The Royal Free Hospital Not yet recruiting London, United Kingdom, NW3 2QG Principal Investigator: Maria Vilarino-Varela St Marys Hospital Not yet recruiting London, United Kingdom, W21NY Contact: Gillian Hornzee Gillian.Hornzee@imperial.nhs.uk Principal Investigator: Simon Stewart Charing Cross Hospital Not yet recruiting London, United Kingdom, W68RF Contact: Simon Stewart simon.stewart@imperial.nhs.uk Principal Investigator: Simon Stewart Christie Hospital Recruiting Manchester, United Kingdom, M20 4BX Contact: Tony Eliott 01619187214 tony.eliott@christie.nhs.uk Principal Investigator: Tony Eliott Mount Vernon Hospital Recruiting Northwood Middlesex, United Kingdom, HA6 2RN Contact: Peter Hoskin 01923 844533 peter.hoskin@nhs.net Principal Investigator: Peter Hoskin Churchill Hospital Recruiting Oxford, United Kingdom, OX37LJ Contact: Georgina Rogers patpandrewprotheroe@oncology.ox.ac.uk Principal Investigator: Andrew Protheroe Weston Park Hospital Recruiting Sheffield, United Kingdom, S102SJ Contact: Linda Evans 0114 226500 linda.evans@sth.nhs.uk Principal Investigator: Linda Evans Southampton General Hospital Recruiting Southampton, United Kingdom, S016 6YD Contact: Simon Crabb s.j.crabb@southampton.ac.uk Principal Investigator: Simon Crabb Royal Surrey County Hospital Recruiting Surrey, United Kingdom, GU27XX Contact: Katie Wood 01483 571122 katiewood@nhs.net Principal Investigator: Katie Wood The Royal Marsden Hospital Recruiting Surrey, United Kingdom, KT2 7QB Contact: Robert Huddart 020 8661 3457 robert.huddart@icr.ac.uk Principal Investigator: Robert Huddart 收起 <<
NCT02015065	GIST	Phase 2	Active, not recruiting	August 31, 2023	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01601808	Pancreatic Cancer	Phase 2	Unknown	October 2013	United Kingdom ... 展开 >> Belfast City Hospital Not yet recruiting Belfast, United Kingdom, BT9 7AB Principal Investigator: Dr Martin Eatock The Royal Bournemouth Hospital Recruiting Bournemouth, United Kingdom, BH7 7DW Principal Investigator: Dr Tamas Hickish Bristol Haematology and Oncology Centre Not yet recruiting Bristol, United Kingdom, BS2 8ED Principal Investigator: Dr Stephen Falk Royal Surrey County Hospital Recruiting Guildford, United Kingdom, GU2 7XX Principal Investigator: Dr Gary Middleton Clatterbridge Centre for Oncology Recruiting Liverpool, United Kingdom, CH63 4JY Principal Investigator: Professor Daniel Palmer Royal Liverpool University Hospital Recruiting Liverpool, United Kingdom, L69 3GA Principal Investigator: Professor Daniel Palmer St Bartholomew's Hospital Not yet recruiting London, United Kingdom, EC1A 7BE Principal Investigator: Dr David Propper Guys & St Thomas Hospital Recruiting London, United Kingdom, SE1 9RT Principal Investigator: Dr Paul Ross Royal Marsden Hospital Not yet recruiting London, United Kingdom, SW3 6JJ Principal Investigator: Professor David Cunningham The Christie Hospital Recruiting Manchester, United Kingdom, M20 4BX Principal Investigator: Dr Richard Hubner James Cook University Hospital Recruiting Middlesbrough, United Kingdom, TS4 3BW Principal Investigator: Dr Nick Wadd Freeman Hospital Not yet recruiting Newcastle, United Kingdom, NE7 7DN Principal Investigator: Dr Fareeda Coxon Nottingham City Hospital Recruiting Nottingham, United Kingdom, NG5 1PB Principal Investigator: Dr Srinivasan Madhusudan Weston Park Hospital Recruiting Sheffield, United Kingdom, S10 2SJ Principal Investigator: Dr Jonathan Wadsley 收起 <<
NCT00996723	Diffuse Intrinsic Pontine Glio... 展开 >>ma 收起 <<	Phase 1	Completed	-	United States, Tennessee ... 展开 >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 收起 <<
NCT00660725	Advanced Incurable Solid Malig... 展开 >>nancy 收起 <<	Phase 1	Completed	-	United States, Pennsylvania ... 展开 >> University of Pittsburgh Cancer Institute / Hillman Cancer Center Pittsburgh, Pennsylvania, United States, 15232 收起 <<
NCT00514046	Medullary Thyroid Carcinoma ... 展开 >> Multiple Endocrine Neoplasia Type 2A Multiple Endocrine Neoplasia Type 2B 收起 <<	Phase 1 Phase 2	Active, not recruiting	July 27, 2022	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01941849	Phaeochromocytoma ... 展开 >> Paraganglioma 收起 <<	Phase 1	Withdrawn(Poor patient accrual... 展开 >>) 收起 <<	-	United Kingdom ... 展开 >> Guy's and St Thomas' NHS Foundation Trust London, United Kingdom The Christie NHS Foundation Trust London, United Kingdom University College London Hospitals NHS Foundation Trust London, United Kingdom 收起 <<
NCT01496313	Thyroid Cancer	Phase 4	Active, not recruiting	December 2019	United States, Texas ... 展开 >> Research Site Houston, Texas, United States Czech Republic Research Site Olomouc, Czech Republic Research Site Praha 5, Czech Republic India Research Site Bangalore Karnataka, India Research Site Vellore, India Israel Research Site Beer Sheva, Israel Research Site Haifa, Israel Research Site Jerusalem, Israel Research Site Petach Tikva, Israel Italy Research Site Catania, Italy Research Site Milano, Italy Research Site Palermo, Italy Research Site Pisa, Italy Research Site Roma, Italy Research Site Siena, Italy Research Site Torino, Italy Netherlands Research Site Groningen, Netherlands Research Site Leiden, Netherlands Poland Research Site Gliwice, Poland Research Site Warszawa, Poland Research Site Zgierz, Poland Russian Federation Research Site Saint Petersburg, Russian Federation United Kingdom Research Site Cardiff, United Kingdom Research Site Greater London, United Kingdom Research Site London, United Kingdom Research Site Tyne & Wear, United Kingdom 收起 <<
NCT01004419	Carcinoma, Non Small Cell Lung	Phase 1	Withdrawn(Support for investig... 展开 >>ational products has been withdrawn.) 收起 <<	May 2011	-
NCT00472017	Brain and Central Nervous Syst... 展开 >>em Tumors 收起 <<	Phase 1	Completed	-	United States, Tennessee ... 展开 >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 收起 <<
NCT02495103	Renal Cell Carcinoma ... 展开 >> Hereditary Leiomyomatosis and Renal Cell Cancer Papillary Renal Cell Carcinoma, Sporadic 收起 <<	Phase 1 Phase 2	Recruiting	May 1, 2022	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT02530411	Neoplasms	Phase 2	Recruiting	December 2020	United Kingdom ... 展开 >> Royal Bournemouth Hospital Recruiting Bournemouth, Dorset, United Kingdom, BH7 7DW Contact: Tamas Hickish, MA MD FRCP 01202 704789 tamashickish@rbch.nhs.uk Royal Devon and Exeter Hospital Recruiting Exeter, England, United Kingdom, EX2 5DW Contact: Anne Hong, MB ChB MRCP 01392 402118 anne.hong@nhs.net Royal Cornwall Hospital Recruiting Truro, Cornwall, England, United Kingdom, TR1 3LJ Contact: Duncan Wheatley, MBBS, FRCR 01872 258304 duncan.wheatley@rcht.cornwall.nhs.uk Velindre Cancer Center, Velindre Hospital Recruiting Cardiff, Wales, United Kingdom, CF14 2TL Contact: Robert Jones, MD PhD MCRCP 029 2061 5888 robert.jones14@wales.nhs.uk Royal United Hospital Bath Recruiting Bath, United Kingdom, BA1 3NG Contact: Mark Beresford, MD MRCP FRCR 01225 824797 mark.beresford@nhs.net 收起 <<
NCT01586624	Cancer Non Sm... 展开 >>all Cell Lung Cancer 收起 <<	Phase 1	Active, not recruiting	March 2019	United Kingdom ... 展开 >> Cambridge Cancer Trials Centre (S4), Box 279, Addenbrooke's Hospital Hills Road, Cambridge, United Kingdom, CB2 0QQ The Christie NHS Foundation Trust Withington, Manchester, United Kingdom, M20 4BX Churchill Hospital Headington, Oxford, United Kingdom, OX3 7LJ The Freeman Hospital Newcastle, United Kingdom, NE7 7DN 收起 <<
NCT00923247	-		Terminated(Terminated due to s... 展开 >>low accrual,primary endpoint reached & investigator left NIH.) 收起 <<	-	-
NCT00923247	Medullary Thyroid Carcinoma	Phase 1 Phase 2	Terminated(Terminated due to s... 展开 >>low accrual,primary endpoint reached & investigator left NIH.) 收起 <<	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT02109250	-		Completed	-	Belgium ... 展开 >> Clinique du Sud Luxembourg Arlon, Belgium, 6700 AZ Klina Brasschaat, Belgium, 2930 Institut Jules Bordet Brussels, Belgium, 1000 UZ Brussel Brussels, Belgium, 1090 UCL St-Luc Brussels, Belgium, 1200 UZ Gent Gent, Belgium, 9000 AZ Delta Roeselare, Belgium, 8800 CH de Wallonie Tournai, Belgium, 7500 收起 <<
NCT00821080	Glioblastoma	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Instiute Boston, Massachusetts, United States, 02115 收起 <<
NCT01582191	Advanced Cancers	Phase 1	Recruiting	May 2026	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 收起 <<
NCT01934335	Invasive Breast Cancer	Phase 2	Suspended(Drugs unavailable)	July 2019	United States, Iowa ... 展开 >> University of Iowa Hospitals and Clinics Iowa City, Iowa, United States, 52242 收起 <<
NCT01876784	-		Active, not recruiting	-	-
NCT01876784	Differentiated Thyroid Cancer	Phase 3	Active, not recruiting	December 31, 2019	-
NCT01298323	Locally Advanced or Metastatic... 展开 >> Medullary Thyroid Cancer Medullary Thyroid Cancer 收起 <<	Phase 3	Active, not recruiting	December 31, 2019	-
NCT01496313	-		Active, not recruiting	-	-
NCT00613223	Gliosarcoma G... 展开 >>lioblastoma 收起 <<	Phase 1	Completed	-	United States, North Carolina ... 展开 >> Duke University Health System Durham, North Carolina, United States, 27710 收起 <<
NCT01298323	-		Active, not recruiting	-	-
NCT01661179	Unresectable Locally Advanced ... 展开 >>or Metastatic, Medullary Thyroid Carcinoma 收起 <<	Phase 1 Phase 2	Completed	-	Japan ... 展开 >> Research Site Fukuoka-shi, Japan Research Site Kobe-shi, Japan Research Site Koto-ku, Japan Research Site Shinjuku-ku, Japan 收起 <<
NCT01661179	-		Completed	-	-
NCT01539655	Medullary Thyroid Cancer	Phase 1	Completed	-	United States, Kansas ... 展开 >> Research Site Overland Park, Kansas, United States 收起 <<
NCT01551615	Healthy	Phase 1	Completed	-	United States, Kansas ... 展开 >> Research Site Overland Park, Kansas, United States 收起 <<
NCT00566995	Renal Cancer ... 展开 >>Von Hippel Lindau 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01823068	Non Small Cell Lung Cancer	Phase 2	Unknown	July 2018	Korea, Republic of ... 展开 >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 110744 Principal Investigator: Se-Hoon Lee, M.D., Ph.D. Samsung Medical Center Recruiting Seoul, Korea, Republic of, 135710 Principal Investigator: Myung-Ju Ahn, M.D. 收起 <<
NCT01561781	Healthy Volunteers	Phase 1	Completed	-	United States, Kansas ... 展开 >> Research Site Overland Park, Kansas, United States 收起 <<
NCT03291379	Carcinoma, Hepatocellular ... 展开 >> Metastatic Colorectal Cancer 收起 <<	Early Phase 1	Recruiting	January 2019	United Kingdom ... 展开 >> University College London Hospital Recruiting Bloomsbury, London, United Kingdom, NW1 2BU Contact: Professor Ricky Sharma 收起 <<
NCT00566995	-		Completed	-	-
NCT01544140	Healthy Volunteers	Phase 1	Completed	-	United States, Kansas ... 展开 >> Research Site Overland Park, Kansas, United States 收起 <<

靶点	EGFR/ErbB1 EGFR, IC50:500 nM VEGFR3 VEGFR3, IC50:110 nM VEGFR2 VEGFR2, IC50:40 nM
描述	VEGF/VEGFR (vascular endothelial growth factor vascular endothelial growth factor receptor) pathway plays a key role in tumor angiogenesis by promotion of vascular and lymphatic endothelial, as well as survival, and invasion, thus resulting in neovascularization, tumor growth and metastasis. Vandetanib is a selective VEGFR2 inhibitor with IC50 value of 40nM versus IC50 of 110nM/1600nM for VEGFR3/VEGFR1, also show inhibitory potency to EGFR, PDGFRβ, Tie-2 and FGFR1 with IC50 values of 0.5μM, 1.1μM, 2.5μM and 3.6μM, respectively, in kinase activity assays. Consistent with the selectivity for inhibition of the different RTKs, Vandetanib showed most potency to VEGF-stimulated HUVEC proliferation with IC50 value of 60nM, versus IC50 values of 170 and 800nM for EGF- and bFGF-stimulated cell growth, respectively^[1]. The inactivation by Vandetanib on kinase activity of its targets was confirmed by the cellular studies as exposure to Vandetanib at concentration of 1, 5 and 10μM caused inhibition of VEGF-induced p-VEGFR2 in HUVECs, as well as suppressed EGF-induced p-EGFR in the hepatoma cell lines^[2]. Vandetanib showed anti-proliferative effect on A549 tumor cells at concentration ranging in 2.7±0.5μM and Calu-6 tumor cells at concentration ranging in 13.5±1.5μM, 45- and 225-fold more than those to inhibit VEGF-stimulated HUVEC proliferation. As prediction of its effect on VEGFR, the significant anti-angiogenesis by Vandetanib can be observed in mice intradermally implanted A549 tumor cells with reduction of tumor-induced blood vessel formation by 63%/79% at dose of 50/100mg/kg/day, orally, for 5 days. Oral administration of Vandetanib once daily produced anti-tumor effect in a dose-dependent manner in all tested models from different origins, including Calu-6 (lung), PC-3 (prostate), MDA-MB-231 (breast), SKOV-3 (ovary), SW620 (colon), A549 (lung), A431 (vulva), B16-F10(AP3) (murine melanoma) and Lewis Lung (murine lung) xenografts, at dose of 12.5, 25, 50 and 100mg/kg^[1].
作用机制	Vandetanib is an ATP-competitive inhibitor of VEGFR, EGFR and RET kinases.^[3]

CAS号	443913-73-3
分子式	C₂₂H₂₄BrFN₄O₂
分子量	475.35
SMILES Code	CN1CCC(COC2=CC3=NC=NC(NC4=CC=C(Br)C=C4F)=C3C=C2OC)CC1
MDL No.	MFCD07772346

别名	凡德他尼(ZD6474) ;ZD6474; CH 331; Zactima
运输	蓝冰
InChI Key	UHTHHESEBZOYNR-UHFFFAOYSA-N
Pubchem ID	3081361

EGFR/ErbB1	EGFR, IC50:500 nM
VEGFR3	VEGFR3, IC50:110 nM
VEGFR2	VEGFR2, IC50:40 nM

Vandetanib/凡德他尼 {[allProObj[0].p_purity_real_show]}

Vandetanib/凡德他尼纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Vandetanib/凡德他尼质控信息

Vandetanib/凡德他尼生物活性

Vandetanib/凡德他尼细胞实验

Vandetanib/凡德他尼动物实验

Vandetanib/凡德他尼动物研究

Vandetanib/凡德他尼临床研究

Vandetanib/凡德他尼参考文献

Vandetanib/凡德他尼实验方案

Vandetanib/凡德他尼技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Vandetanib/凡德他尼 {[allProObj[0].p_purity_real_show]}

Vandetanib/凡德他尼 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Vandetanib/凡德他尼 质控信息

Vandetanib/凡德他尼 生物活性

Vandetanib/凡德他尼 细胞实验

Vandetanib/凡德他尼 动物实验

Vandetanib/凡德他尼 动物研究

Vandetanib/凡德他尼 临床研究

Vandetanib/凡德他尼 参考文献

Vandetanib/凡德他尼 实验方案

Vandetanib/凡德他尼 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Vandetanib/凡德他尼纯度/质量文件产品仅供科研

Vandetanib/凡德他尼质控信息

Vandetanib/凡德他尼生物活性

Vandetanib/凡德他尼细胞实验

Vandetanib/凡德他尼动物实验

Vandetanib/凡德他尼动物研究

Vandetanib/凡德他尼临床研究

Vandetanib/凡德他尼参考文献

Vandetanib/凡德他尼实验方案

Vandetanib/凡德他尼技术信息